4.6 Article

Genetic and Functional Diversity of Propagating Cells in Glioblastoma

期刊

STEM CELL REPORTS
卷 4, 期 1, 页码 7-15

出版社

CELL PRESS
DOI: 10.1016/j.stemcr.2014.11.003

关键词

-

资金

  1. National Institute for Health Research
  2. Cambridge Biomedical Research Centre
  3. Higher Education Funding Council for England
  4. Royal College of Surgeons of Edinburgh
  5. Brain Tumour Charity
  6. European Commission-Seventh Framework Programme (Marie Curie Intra-European Fellowship)
  7. Wellcome Trust
  8. MRC [G108/507] Funding Source: UKRI
  9. Cancer Research UK [16700] Funding Source: researchfish
  10. Medical Research Council [G108/507] Funding Source: researchfish
  11. The Brain Tumour Charity [10/136] Funding Source: researchfish

向作者/读者索取更多资源

Glioblastoma (GBM) is a lethal malignancy whose clinical intransigence has been linked to extensive intraclonal genetic and phenotypic diversity and the common emergence of therapeutic resistance. This interpretation embodies the implicit assumption that cancer stem cells or tumor-propagating cells are themselves genetically and functionally diverse. To test this, we screened primary GBM tumors by SNP array to identify copy number alterations (a minimum of three) that could be visualized in single cells by multicolor fluorescence in situ hybridization. Interrogation of neurosphere-derived cells (from four patients) and cells derived from secondary transplants of these same cells in NOD-SCID mice allowed us to infer the clonal and phylogenetic architectures. Whole-exome sequencing and single-cell genetic analysis in one case revealed a more complex clonal structure. This proof-of-principle experiment revealed that subclones in each GBM had variable regenerative or stem cell activity, and highlighted genetic alterations associated with more competitive propagating activity in vivo.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Resveratrol: A New Potential Therapeutic Agent for Melanoma?

Mohamad Hossein Pourhanifeh, Kazem Abbaszadeh-Goudarzi, Mohammad Goodarzi, Sara G. M. Piccirillo, Alimohammad Shafiee, Sarah Hajighadimi, Sanaz Moradizarmehri, Zatollah Asemi, Hamed Mirzaei

Summary: Melanoma, the most life-threatening skin malignancy, has steadily increasing incidence. Resveratrol, a polyphenol found in grapes, exhibits anti-cancer properties but requires more clinical trials for efficacy validation.

CURRENT MEDICINAL CHEMISTRY (2021)

Article Hematology

Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia

Yuzhe Shi, Melanie C. Beckett, Helen J. Blair, Ricky Tirtakusuma, Sirintra Nakjang, Amir Enshaei, Christina Halsey, Josef Vormoor, Olaf Heidenreich, Anja Krippner-Heidenreich, Frederik W. van Delft

Summary: The study identified the critical role of LCK in T-cell acute lymphoblastic leukemia (T-ALL) cell proliferation, with combination therapy of LCK inhibition with dasatinib (DAS) leading to cell death, which was enhanced by dexamethasone (DEX). These findings provide a strategy to improve the efficacy of current chemotherapy and overcome glucocorticoid resistance in high-risk T-ALL patients.

HAEMATOLOGICA (2021)

Article Radiology, Nuclear Medicine & Medical Imaging

In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients

Vivek Tiwari, Tomoyuki Mashimo, Zhongxu An, Vamsidhara Vemireddy, Sara Piccirillo, Pegah Askari, Keith M. Hulsey, Shanrong Zhang, Robin A. de Graaf, Toral R. Patel, Edward Pan, Bruce E. Mickey, Elizabeth A. Maher, Robert M. Bachoo, Changho Choi

MAGNETIC RESONANCE IN MEDICINE (2020)

Article Hematology

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia

Ing S. Tiong, Richard Dillon, Adam Ivey, Tse-Chieh Teh, Phillip Nguyen, Nicholas Cummings, David C. Taussig, Annie-Louise Latif, Nicola E. Potter, Manohursingh Runglall, Nigel H. Russell, Kavita Raj, Anthony P. Schwarer, Chun Yew Fong, Andrew P. Grigg, Andrew H. Wei

Summary: This study demonstrates the significant efficacy of venetoclax-based therapy in reducing the risk of relapse in patients with persistent or rising NPM1(mut) MRD.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Review Hematology

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

Richard Dillon, Nicola Potter, Sylvie Freeman, Nigel Russell

Summary: Recent years have seen significant advances in the use of molecular diagnostic and monitoring techniques for patients with acute myeloid leukaemia (AML), coupled with the development of new therapeutic agents. This has led to potential improvements in treatment algorithms. The article highlights the importance of molecular monitoring in refining clinical decision-making and personalizing treatment for AML patients, with practical recommendations provided for cases where evidence is lacking or conflicting. Additionally, important technical considerations for clinicians to safely utilize these technologies are reviewed as they become more widely implemented.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Letter Oncology

Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis

Richard Dillon, Matthew J. Ahearne, Lynn Quek, Nicola Potter, Jelena Jovanovic, Nicola Foot, Mikel Valganon, Sandrine Jayne, Mike Dennis, Kavita Raj, Sudhir Tauro, Martin J. S. Dyer, Nigel Russell, Ellen Solomon, David Grimwade

LEUKEMIA (2021)

Article Hematology

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Ing S. Tiong, Richard Dillon, Adam Ivey, James A. Kuzich, Nisha Thiagarajah, Kirsty M. Sharplin, Chung Hoow Kok, Aditya Tedjaseputra, James P. Rowland, Carolyn S. Grove, Emad Abro, Jake Shortt, Devendra K. Hiwase, Ashish Bajel, Nicola E. Potter, Matthew L. Smith, Claire J. Hemmaway, Abin Thomas, Amanda F. Gilkes, Nigel H. Russell, Andrew H. Wei

Summary: Monitoring of NPM1 mutant measurable residual disease in AML patients treated with intensive chemotherapy is crucial. Persistence of low copy number MRD post-treatment is associated with disease progression, with preemptive salvage therapy showing significant benefits. Risk factors for disease progression include FLT3-internal tandem duplication at diagnosis and suboptimal MRD response at EOT.

BLOOD ADVANCES (2021)

Letter Hematology

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Sun Loo, Richard Dillon, Adam Ivey, Natasha S. Anstee, Jad Othman, Ing Soo Tiong, Nicola Potter, Jelena Jovanovic, Manohursingh Runglall, Chyn Chua Chong, Ashish Bajel, David Ritchie, Kelli Gray, Zhi Han Yeoh, Michelle McBean, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei

Article Oncology

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Richard Dillon, Shanna Maycock, Aimee Jackson, Sonia Fox, Sylvie Freeman, Charles Craddock, Catherine Thomas, Emma Homer, Jane Leahy, Anna Mamwell, Nicola Potter, Nigel Russell, Andrew Wei, Hans Beier Ommen, Claire Hemmaway, Steve Knapper, Lucinda Billingham

Summary: The VICTOR trial is evaluating the non-inferiority of intensive chemotherapy and Venetoclax with low-dose cytarabine in older patients with AML. The trial employs an innovative Bayesian design and will expand to include younger patients if there is sufficient evidence of non-inferiority.

BMC CANCER (2022)

Review Oncology

Dissecting Intra-tumor Heterogeneity in the Glioblastoma Microenvironment Using Fluorescence-Guided Multiple Sampling

Leopoldo A. Garcia-Montano, Yamhilette Licon-Munoz, Frank J. Martinez, Yasine R. Keddari, Michael K. Ziemke, Muhammad O. Chohan, Sara G. M. Piccirillo

Summary: The treatment of glioblastoma (GBM), the most aggressive primary brain tumor in adults, is difficult due to its heterogeneous nature, invasive potential, and poor response to therapy. GBM is characterized by extensive phenotypic and genetic heterogeneity, which promote tumor growth and resistance to treatment. Dissecting this heterogeneity is challenging, and current research focuses on the use of fluorescence-guided multiple sampling to understand GBM microenvironment and identify potential therapeutic targets.

MOLECULAR CANCER RESEARCH (2023)

Letter Oncology

Unusual relapse of low hypodiploid acute lymphoblastic leukaemia in a family with Li-Fraumeni syndrome

Frederik W. van Delft, Simon Bailey, Roderick Skinner, Geoff Shenton, Peter Carey, Quentin Campbell-Hewson, Juliet Hale, Leigh McDonald, Kate Pearce, Richard Martin, Katrina Robinson, Gavin Cuthbert

PEDIATRIC BLOOD & CANCER (2023)

Article Hematology

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

Stuart Scott, Richard Dillon, Christian Thiede, Sadia Sadiq, Ashley Cartwright, Hazel J. Clouston, Debbie Travis, Katya Mokretar, Nicola Potter, Andrew Chantry, Liam Whitby

Summary: The European LeukaemiaNet (ELN) MRD working group has published guidelines for standardizing molecular genetic MRD testing of certain markers. A study involving 29 international laboratories showed that most participants were able to accurately detect and interpret MRD testing results, although some errors were identified. False-positive results were reported in the NPM1 marker-negative samples, emphasizing the need for ongoing quality assessment and proficiency testing. The study also highlighted the need for revising the guidelines to address interpretive issues and improve dissemination.

BLOOD ADVANCES (2023)

Article Hematology

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna Canham, Emily L. Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

Summary: This study compared the efficacy of CPX-351 and FLAG-Ida in younger patients, and found no significant difference in overall survival between the two treatments. However, the use of CPX-351 significantly prolonged relapse-free survival, particularly in patients with MDS-related gene mutations.

BLOOD ADVANCES (2023)

Article Oncology

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Jad Othman, Nicola Potter, Katya Mokretar, David Taussig, Anjum Khan, Pramila Krishnamurthy, Anne-Louise Latif, Paul Cahalin, James Aries, Mariam Amer, Edward Belsham, Eibhlin Conneally, Charles Craddock, Dominic Culligan, Mike Dennis, Caroline Duncan, Sylvie D. Freeman, Caroline Furness, Amanda Gilkes, Paraskevi Gkreka, Katherine Hodgson, Wendy Ingram, Manish Jain, Andrew King, Steven Knapper, Panagiotis Kottaridis, Mary Frances McMullin, Unmesh Mohite, Loretta Ngu, Jenny O'Nions, Katharine Patrick, Tom Rider, Wing Roberts, Marianne Tang Severinsen, Neill Storrar, Tom Taylor, Nigel H. Russell, Richard Dillon

Summary: Patients with FLT3-mutated AML are at high risk of relapse and poor outcomes. Monitoring measurable residual disease (MRD) can help identify patients destined to relapse, providing an opportunity for pre-emptive intervention. In this study, 56 patients with molecular failure were treated with FLT3 inhibitors (FLT3i), resulting in a molecular response rate of 60% and an overall survival rate of 80% at 2 years. High-sensitivity next-generation sequencing identified patients more likely to benefit from FLT3i monotherapy. Further prospective studies are warranted to evaluate this promising treatment strategy.

LEUKEMIA (2023)

Article Oncology

Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia

Virginia A. Turati, Jose Afonso Guerra-Assuncao, Nicola E. Potter, Rajeev Gupta, Simone Ecker, Agne Daneviciute, Maxime Tarabichi, Amy P. Webster, Chuling Ding, Gillian May, Chela James, John Brown, Lucia Conde, Lisa J. Russell, Phil Ancliff, Sarah Inglott, Giovanni Cazzaniga, Andrea Biondi, Georgina W. Hall, Mark Lynch, Mike Hubank, Iain Macaulay, Stephan Beck, Peter Van Loo, Sten E. Jacobsen, Mel Greaves, Javier Herrero, Tariq Enver

Summary: Enver and colleagues found that epigenetic cell state, rather than genetic diversity, plays a key role in bottleneck selection of subclonal genotypes during induction chemotherapy in childhood B-cell precursor acute lymphoblastic leukemia. The study also suggests that chemotherapy affects transcriptional and epigenetic heterogeneity in BCP-ALL, resulting in a phenotypically uniform population. Overall, the research highlights the importance of cell state canalization in bottleneck selection during induction chemotherapy.

NATURE CANCER (2021)

暂无数据